Cresco Labs Inc. (CRLBF) Reports Q4 Loss, Beats Revenue Estimates

分组1 - Cresco Labs Inc. reported a quarterly loss of $0.02 per share, matching the Zacks Consensus Estimate, compared to a loss of $0.01 per share a year ago, indicating an earnings surprise of +14.16% [1] - The company posted revenues of $161.55 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.26%, but down from $175.91 million year-over-year [2] - Cresco Labs shares have declined approximately 20.7% since the beginning of the year, while the S&P 500 has gained 0.4% [3] 分组2 - The earnings outlook for Cresco Labs is uncertain, with current consensus EPS estimates at -$0.03 for the coming quarter and -$0.09 for the current fiscal year, with revenues expected to be $162 million and $670.41 million respectively [7] - The Zacks Industry Rank for Medical - Products is in the bottom 45% of over 250 Zacks industries, indicating that the industry outlook may negatively impact stock performance [8] - The estimate revisions trend for Cresco Labs was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]